Clinical experience with PSMA-targeting positron emission tomography (PET), especially with [68Ga]Ga-PSMA-11 [7,8,9,10,11,12,13,14], in patients with recurrent prostate cancer show that lesions can be detected in almost all patients, in some cases with very low PSA levels. The gene discussed is FOLH1; the disease is prostate carcinoma.